KalVista Pharmaceuticals, Inc.
KALV
$13.55
-$0.05-0.37%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -67.11% | -52.86% | -59.75% | -69.74% | -36.26% |
| Total Depreciation and Amortization | 10.63% | 15.23% | 16.06% | 16.49% | 4.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 338.43% | -42.80% | -11.63% | 441.76% | 16.79% |
| Change in Net Operating Assets | 641.96% | -94.41% | 45.25% | 1,364.73% | -110.47% |
| Cash from Operations | -18.53% | -99.96% | -50.47% | 33.27% | -196.81% |
| Capital Expenditure | -26.32% | -5,300.00% | -250.00% | 78.26% | -26.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 227.80% | 70.81% | 89.53% | -1,954.57% | -167.11% |
| Cash from Investing | 227.08% | 70.45% | 89.48% | -1,931.98% | -166.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19,809.51% | 130.47% | 1,370.59% | -- | -99.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 17,607.67% | -- |
| Cash from Financing | 53,341.20% | 130.47% | 1,370.59% | 454,942.42% | -99.51% |
| Foreign Exchange rate Adjustments | -101.13% | 167.61% | 39.29% | -208.82% | -235.89% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 465.10% | 17.88% | 100.86% | 130.31% | -174.49% |